Search results for "anti-TNF"
showing 10 items of 19 documents
No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study.
2013
OBJECTIVES: The widespread use of tumour necrosis factor (TNF)-targeted therapies in patients with rheumatic, digestive and dermatologic diseases has been associated with reports of reactivation of HBV replication and ensuing hepatitis flares both in asymptomatic HBsAg carriers and in subjects with occult HBV infection. The aim of our work was to investigate in a two-year prospective study the potential for HBV reactivation in patients with inflammatory joint diseases undergoing anti-TNF treatment from a southern Mediterranean area. METHODS: Fifty-seven consecutive outpatients attending the Academic Unit of Rheumatology at the University of Palermo (12 with rheumatoid arthritis, 17 with pso…
Medikamentöse Schädigung der Leber mit autoimmunem Phänotyp durch TNF-Blockade – Fallvorstellung und Review der Literatur
2014
Die Zulassung von Medikamenten, die die biologische Wirkung von Tumor-Nekrose-Faktor alpha (TNF-α) blockieren, hat die Behandlungsmoglichkeiten von Patienten mit einer Reihe von autoimmun-vermittelten Erkrankungen stark verbessert. Als haufige Nebenwirkung kommt es zu einer gesteigerten Anfalligkeit gegenuber Infekten. Selten treten auch hepatische Nebenwirkungen unter TNF-Blockade auf. Diese reichen von einer moderaten Leberwert- und Bilirubinerhohung uber die Reaktivierung von chronischen Viruserkrankungen, konnen aber auch zum akuten Leberversagen fuhren. In einem Teil der Falle wurde ein autoimmunes Schadigungsmuster mit dem Auftreten von Autoantikorpern und entsprechenden typischen his…
Evaluation of Changes in Gut Microbiota in Patients with Crohn’s Disease after Anti-Tnfα Treatment: Prospective Multicenter Observational Study
2020
Background: Crohn’s disease is believed to result from the interaction between genetic susceptibility, environmental factors and gut microbiota, leading to an aberrant immune response. The objectives of this study are to evaluate the qualitative and quantitative changes in the microbiota of patients with Crohn’s disease after six months of anti-tumor-necrosis factor (anti-TNFα) (infliximab or adalimumab) treatment and to determine whether these changes lead to the recovery of normal microbiota when compared to a control group of healthy subjects. In addition, we will evaluate the potential role of the Faecalibacterium prausnitzii/Escherichia coli and Faecalibacterium prausnitzii/Clostridium…
Influenze della terapia con anti-TNF sulla concentrazione delle lipoproteine plasmatiche e sul rischio cardiovascolare nei pazienti affetti da Artrit…
2011
Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents.
2020
This is the peer reviewed version of the following article: Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents. Journal of Gastroenterology and Hepatology (2020): 29 April, which has been published in final form at https://doi.org/10.1111/jgh.15084. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions
Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in De…
2020
Background: Registry studies broadly describing the safety of systemic drugs in psoriasis are needed. Objective: To describe the safety findings of the systemic drugs acitretin, adalimumab, apremilast, cyclosporine, etanercept, infliximab, methotrexate, secukinumab, and ustekinumab used for the treatment of moderate to severe psoriasis in patients included in the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry. Methods: The incidence rate ratio (IRR) and adjusted IRR (including propensity scores) of identified adverse events for each drug, using methotrexate as reference, were determined by means of a prospective cohort. Results: O…
Leishmaniasis, autoimmune rheumatic disease, and anti–tumor necrosis factor therapy, Europe.
2009
We report 2 cases of leishmaniasis in patients with autoimmune rheumatic diseases in Greece. To assess trends in leishmaniasis reporting in this patient population, we searched the literature for similar reports from Europe. Reports increased during 2004–2008, especially for patients treated with anti–tumor necrosis factor agents.
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept…
2012
Objective: To evaluate the risk of serious infections (SIs) in RA patients receiving anti-TNF therapy on the basis of the data included in the GISEA register. METHODS: The study involved 2769 adult patients with long-standing RA (mean age 53.2±13.4years; mean disease duration 9.0±8.3years) enrolled in the GISEA register, who had been treated for at least 6months with TNF inhibitors or had discontinued therapy due to SI: 837 (30%) treated with infliximab (IFN), 802 (29%) with adalimumab (ADA), and 1130 (41%) with etanercept (ETN). RESULTS: 176 patients had experienced at least one of the 226 Sis during the 9years of treatment with an anti-TNF agent, an overall incidence of 31.8/1000 patient-…
Intérêt des méthodes alternatives dans l’évaluation du médicament dans les populations particulières
2020
Well conducted randomized clinical trial is considered gold standard in drug safety and efficacy evaluation. Drug development can be challenging in rare diseases, or in ethically sensitive populations (pregnant women, children, patient with cognitive defect), because of low number of subjects. The low rate of observed events at a sample scale in this population can lead to a biased evaluation of drugs compared to the general population. The aim of this work was to address alternative methods for drug evaluation in particular populations, especially pharmaco-epidemiology on populational database of the SNDS (Système National des Données de Santé). We first evaluate the safety of anti-TNFα in…
Sinergismo d'azione tra protocollo riabilitativo ed anti-TNFalfa versus terapia biologica
2012
La spondilite anchilosante è una malattia infiammatoria cronica ad eziologia sconosciuta che colpisce prevalentemente lo scheletro assile ma che può coinvolgere anche le entesi periferiche. Presso l'ambulatorio dell'U.O.C. di Riabilitazione dell'A.U.O.P. "Paolo Giaccone" di Palermo, in diciotto mesi (Aprile 2011-Maggio 2012) sono stati arruolati 24 soggetti (6 donne- 18 uomini). affetti da Spondilite Anchilosante HLA B27 diagnosticata secondo i criteri europei. Il presente studio ha mostrato efficacia nel trattamento di pazienti con SA mediante un progetto-programma riabilitativo mirato e specifico per distretto articolare. Svolgere con regolarità e costanza l'esercizio terapeutico in assoc…